Aeglea BioTherapeutics

Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

AUSTIN, Texas, Nov. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in...

Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences

Aeglea (AGLE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Aeglea (AGLE) This Earnings Season?

Billionaire investor Steven Cohen (Trades, Portfolio) revealed a new stake in Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) late last week.

Steven Cohen Jumps Back Into Aeglea BioTherapeutics

AUSTIN, Texas, Oct. 26, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced the U.S. Food and Drug...

Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria

AUSTIN, Texas, Oct. 5, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced the presentation of a...

Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings

AUSTIN, Texas, Sept.  02, 2020  (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in three investor conferences in September 2020, including presenting at the H.C. Wainwright 22nd Annual Global Investment Conference being held virtually on September 14-16, 2020.

Aeglea BioTherapeutics to Participate in September Investment Conferences

Aeglea (AGLE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Aeglea (AGLE) Looks Good: Stock Adds 5.8% in Session

AUSTIN, Texas, Aug.  18, 2020  (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in two presentations at the World Orphan Drug Congress USA 2020 being held virtually August 24-27, 2020.

Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020

Does Aeglea Biotherapeutics (AGLE) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum Investors Will Love Aeglea Biotherapeutics (AGLE)

Is  (AGLE) Outperforming Other Medical Stocks This Year?

Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year?

Dynavax Technologies

Liquidia Technologies Inc

PhaseBio Pharmaceuticals Inc

Seelos Therapeutics

If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify several Top Shorts today.

Top Stocks To Short As Markets Rebound Ignores Disappointing Monday

Aeglea BioTherapeutics (AGLE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Aeglea BioTherapeutics (AGLE) Catches Eye: Stock Jumps 5.1%

Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Aeglea BioTherapeutics (AGLE) Stock Might be a Great Pick

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

New Analyst Coverage Puts Spotlight on These 2 Stocks

As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics

Aeglea BioTherapeutics' Shares March Higher, Can It Continue?

AUSTIN, Tx., May  28, 2020  (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic, the location of the Company’s 2020 annual meeting of stockholders has been changed and will be held in a virtual meeting format only. As previously announced, the annual meeting will be held on Monday, June 8, 2020 at 9:00 a.m. Central Time. To be admitted to the annual meeting at   www.virtualshareholdermeeting.com/AGLE2020 , stockholders must enter the control number found on their proxy card, voting instruction form or notice previously received. Further information regarding this change to the location of the annual meeting can be found in the supplemental proxy materials filed by Aeglea with the Securities and Exchange Commission on May 28, 2020.

Aeglea BioTherapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held June 8, 2020

  Pegzilarginase Showed Durable Clinical Response at 56 Week Analysis

Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology

Is Aeglea BioTherapeutics (AGLE) Outperforming Other Medical Stocks This Year?

Sequans Communications

VeriSign

Find Strong Stocks During the Coronavirus with New Analyst Coverage

Is Aeglea BioTherapeutics (AGLE) Stock a Solid Choice Right Now?

As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics, Inc. (AGLE).

Aeglea BioTherapeutics, Inc. (AGLE) Shares March Higher, Can It Continue?

Aeglea (AGLE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aeglea (AGLE) Upgraded to Strong Buy: What Does It Mean for the Stock?

AUSTIN, Texas, April  30, 2020  (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for rare and other high-burden diseases, today announced the closing of its public offering of 15,442,303 shares of its common stock at a public offering price of $4.75 per share, which includes the exercise in full of the underwriters’ option to purchase 3,789,473 shares of common stock. In addition, and in lieu of common stock, Aeglea sold to certain investors pre-funded warrants to purchase up to an aggregate of 13,610,328 shares of common stock at a purchase price of $4.7499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds to Aeglea, before deducting underwriting discounts and commissions and estimated offering expenses payable by Aeglea, were approximately $138 million.

Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

AUSTIN, Texas, April  28, 2020  (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today announced the pricing of an underwritten public offering of 11,652,830 shares of its common stock at a price to the public of $4.75 per share. In addition, and in lieu of common stock, Aeglea is offering to certain investors pre-funded warrants to purchase up to an aggregate of 13,610,328 shares of common stock at a purchase price of $4.7499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $120 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Aeglea. The offering is expected to close on or about April 30, 2020, subject to customary closing conditions. Aeglea has also granted the underwriters a 30-day option to purchase up to an additional 3,789,473 shares of common stock in connection with the public offering. All of the securities are being offered by Aeglea.

Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering

AUSTIN, Texas, April  08, 2020  (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet medical need, today announced the approval of its Clinical Trial Application (CTA) by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for ACN00177, a novel engineered human enzyme therapy designed to treat Homocystinuria, a serious metabolic disorder characterized by elevated plasma homocysteine levels, leading to a wide range of life-altering complications and reduced life expectancy.

Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

News for Aeglea BioTherapeutics Stock (AGLE)